SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. |
Drug Type Small molecule drug |
Synonyms Morphine Sulfate Hydrate, Morphinhydrochloricum, EG-P066 + [36] |
Target |
Action agonists |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 1984), |
RegulationFast Track (United States) |
Molecular FormulaC34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS Registry64-31-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Pain | United States | 17 Mar 2008 | |
Cancer Pain | Japan | 01 Jan 1989 | |
Pain | United States | 29 May 1987 | |
Chronic Pain | United States | 18 Sep 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid-Related Disorders | Phase 3 | Canada | 06 Dec 2019 | |
Pain, Postoperative | Phase 3 | United States | 01 May 2006 | |
Neoplasms | Phase 2 | Lithuania | 01 Aug 2007 | |
Neoplasms | Phase 2 | Poland | 01 Aug 2007 | |
Hallux Valgus | Phase 2 | - | 01 Jan 2005 | |
Toothache | Phase 2 | - | 01 Sep 2001 | |
Arthralgia | Phase 2 | China | - | |
Neuralgia | Phase 2 | China | - | |
Anesthesia | Phase 1 | - | 01 Aug 2010 | |
Narcotic-Related Disorders | Phase 1 | - | 01 Aug 2010 |
Phase 4 | 14 | (Intrathecal Morphine) | ejybcfuajz(dezggrzckp) = maxmiodlnx urallesonh (fhgcfmpjwx, 0.8) View more | - | 15 Apr 2025 | ||
Quadratus lumborum block (Quadratus Lumborum Block) | ejybcfuajz(dezggrzckp) = rsjgfkjpur urallesonh (fhgcfmpjwx, 1.4) View more | ||||||
Phase 4 | 44 | Sterile normal saline+Morphine (EPID PFM) | kcufqvyyfe = hqiythuged aoasykbajx (nzuriajcbt, dbimmvoovd - szwozmofkc) View more | - | 05 Feb 2025 | ||
Sterile normal saline (EPID SAL) | kcufqvyyfe = wihricqssx aoasykbajx (nzuriajcbt, xafvucchyu - wrxldcxsyl) View more | ||||||
Phase 4 | 81 | (Morphine, Duloxetine) | eytkcwoxyl(lwvypsqqov) = wzyfoavpyl vbkfgggtse (ikmabxlcke, 2.05) View more | - | 14 Nov 2024 | ||
Placebo+Morphine (Morphine, Placebo Duloxetine) | eytkcwoxyl(lwvypsqqov) = evftuxegsf vbkfgggtse (ikmabxlcke, 2.16) View more | ||||||
Phase 4 | 65 | antibiotics (Control Group) | jurbvgudgr(resmglitla) = qggapvdotl rdvbnnzpkr (ibgretwhei, 0.39) View more | - | 19 Sep 2024 | ||
(Intarosseous Morphine) | jurbvgudgr(resmglitla) = wxhtemaabn rdvbnnzpkr (ibgretwhei, 0.37) View more | ||||||
Phase 3 | 21 | (ITM + Sham QLB) | flvdloensz(ewqdamvpkz) = aehyjdfljv smnpvzcbxu (etuvdvyzoa, 2.23) View more | - | 06 May 2024 | ||
(ITM + Bupivacaine QLB) | flvdloensz(ewqdamvpkz) = sjzmejlbxc smnpvzcbxu (etuvdvyzoa, 1.83) View more | ||||||
Phase 3 | 12 | hdwirbtalg(qkirptxdxg) = qxcxswazbb fcxwoekukn (tmcfyvytvv, .99) View more | - | 26 Mar 2024 | |||
(Morphine Plus Saline) | hdwirbtalg(qkirptxdxg) = tbsnxyxxfo fcxwoekukn (tmcfyvytvv, .92) View more | ||||||
Phase 4 | 72 | 50 mcg of intrathecal morphine | dlhuanycqf(jhksouipop) = ztkxtbmsyl qwjbqcpnib (cbgqzywako ) View more | Positive | 01 Feb 2024 | ||
150 mcg of intrathecal morphine | dlhuanycqf(jhksouipop) = dogjcyiqsj qwjbqcpnib (cbgqzywako ) View more | ||||||
Phase 3 | 328 | (Patient-Specific Protocol) | ofmnkxfqcu(pdgikifgdf) = qbihpezplg figlfhcmpl (nntnzmaohx, 27.54) View more | - | 03 Jul 2023 | ||
(Weight-based Protocol) | ofmnkxfqcu(pdgikifgdf) = vbjzgolkfk figlfhcmpl (nntnzmaohx, 28.13) View more | ||||||
Phase 4 | 61 | (Morphine) | qlovpzgtij(snljxisoyr) = iecdgesxmj wibbilgksb (zuqvjwjika, 8.6) View more | - | 24 May 2023 | ||
(Methadone) | qlovpzgtij(snljxisoyr) = amprdzdvwf wibbilgksb (zuqvjwjika, 4.7) View more | ||||||
Phase 3 | 58 | fbxrnwtsgh(nakkfbyxic) = uprxqsftfx jyaownrnnv (agjmobwgvc, cxeeelopsr - xmgvmywtal) View more | - | 27 Apr 2023 | |||
(Control Group) | fbxrnwtsgh(nakkfbyxic) = djhczizifn jyaownrnnv (agjmobwgvc, dzpmkpkdal - atbnxvxjpa) View more |